KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Income from Continuing Operations (2016 - 2025)

Biogen has reported Income from Continuing Operations over the past 17 years, most recently at 48900000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 48900000.0 for Q4 2025, down 118.34% from a year ago — trailing twelve months through Dec 2025 was 1292900000.0 (down 20.79% YoY), and the annual figure for FY2025 was 1292900000.0, down 20.79%.
  • Income from Continuing Operations for Q4 2025 was 48900000.0 at Biogen, down from 466500000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for BIIB hit a ceiling of 1134900000.0 in Q3 2022 and a floor of 68300000.0 in Q3 2023.
  • Median Income from Continuing Operations over the past 5 years was 390950000.0 (2024), compared with a mean of 436920000.0.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 1538.48% in 2022 and later plummeted 118.34% in 2025.
  • Biogen's Income from Continuing Operations stood at 38200000.0 in 2021, then skyrocketed by 1538.48% to 549500000.0 in 2022, then crashed by 54.7% to 248900000.0 in 2023, then rose by 7.15% to 266700000.0 in 2024, then plummeted by 118.34% to 48900000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 48900000.0 (Q4 2025), 466500000.0 (Q3 2025), and 634800000.0 (Q2 2025) per Business Quant data.